StockNews.com assumed coverage on shares of Minerva Neurosciences (NASDAQ:NERV – Free Report) in a research report report published on Wednesday. The brokerage issued a sell rating on the biopharmaceutical company’s stock.
Separately, HC Wainwright cut their price target on Minerva Neurosciences from $7.00 to $5.00 and set a neutral rating for the company in a research note on Wednesday, August 7th.
Get Our Latest Research Report on Minerva Neurosciences
Minerva Neurosciences Stock Up 3.1 %
Minerva Neurosciences (NASDAQ:NERV – Get Free Report) last released its earnings results on Tuesday, August 6th. The biopharmaceutical company reported ($1.09) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.97) by ($0.12). On average, equities analysts anticipate that Minerva Neurosciences will post -2.26 earnings per share for the current fiscal year.
About Minerva Neurosciences
Minerva Neurosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders.
Featured Articles
- Five stocks we like better than Minerva Neurosciences
- Stock Average Calculator
- 3 Momentum Trades for October With Ample Upside Ahead
- Stock Market Sectors: What Are They and How Many Are There?
- Roblox Dips on Short Report—Here’s Why It Could Bounce Back Fast
- Where to Find Earnings Call Transcripts
- 2 Reasons to Jump on Apple Stock Now and 1 Reason to Think Twice
Receive News & Ratings for Minerva Neurosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Minerva Neurosciences and related companies with MarketBeat.com's FREE daily email newsletter.